Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

The suit also accuses J&J of anticipating that the link between Tylenol and autism would be thrust into the spotlight by the ...

Shares in Novartis had fallen nearly 3.5% at the time of writing, as investors digested the third-quarter figures and ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences ...

According to HIV therapy specialist ViiV, which is majority owned by GSK with Pfizer and Shionogi as shareholders, the UK ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and ...

Beyond R&D, AI is transforming the way biopharma companies commercialise therapies and interact with healthcare providers and patients. In a marketplace increasingly driven by personalised experiences ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

While he has resigned, rather than being sacked, Ali has agreed to leave his post without being entitled to any severance ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Lilly's GIP/GLP-1 agonist Mounjaro (tirzepatide) also outperformed Ozempic, and the formulation of the drug for obesity, ...

At ESMO 2025, pharmaphorum caught up with Barry Vucsko, Senior Vice President of Strategic Development, Agency Services, for ...